• Explore /
  • Poster
  • / Preliminary safety, efficacy, and pharmacokinetics (PK) results of KN046 (bispecific anti-PD-L1/CTLA4) from a first-in-human study in subjects with advanced solid tumors.

Preliminary safety, efficacy, and pharmacokinetics (PK) results of KN046 (bispecific anti-PD-L1/CTLA4) from a first-in-human study in subjects with advanced solid tumors.

Abstract Poster

Authors

null

Jermaine Coward

Icon Cancer Care, Brisbane, Australia

Jermaine Coward , Vinod Ganju , Ramin Behzadigohar , Kenneth Kwong , June Xu , Hardy Van , Paul Kong , Fei Yang , Lisa Chen , Kangping Guo , Mei Liu , Danming Zhu , Lara Kristina Donato , Ting Xu , Gary Edward Richardson

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Immunotherapy and Tumor Immunobiology

Track

Developmental Therapeutics—Immunotherapy

Sub Track

Immune Checkpoint Inhibitors

Clinical Trial Registration Number

NCT03529526

Citation

J Clin Oncol 37, 2019 (suppl; abstr 2554)

DOI

10.1200/JCO.2019.37.15_suppl.2554

Abstract #

2554

Poster Bd #

198

Abstract Disclosures

Similar Posters

First Author: Panpan Zhang

First Author: Ye Guo

First Author: Diwakar Davar

Poster

2020 ASCO-SITC Clinical Immuno-Oncology Symposium

A phase Ib study of troriluzole (BHV-4157) in combination with nivolumab.

A phase Ib study of troriluzole (BHV-4157) in combination with nivolumab.

First Author: Ann W. Silk